Screener / SEC EDGAR /CIK 0001601830 /10-K filed Feb 25, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Biotechnology

Recursion Pharmaceuticals, Inc. RXRX

Recursion is a clinical-stage TechBio company with a mission to decode biology to radically improve lives. 10-K, Item 1

Headquarters
Salt Lake City, UT
CEO
Najat Khan
Next results
around Feb 24, 2027
Compare with peers Embed

RXRX among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 26.9%, above 81% of 154 peers (their median 10.4%) REVENUE GROWTH 26.9% · above 81% Gross margin: 5.0%, above 3% of 107 peers (their median 63.8%) GROSS MARGIN 5.0% · above 3% Operating margin: -725.4%, above 1% of 138 peers (their median 10.2%) OPERATING MARGIN -725.4% · above 1% Net margin: -697.1%, above 1% of 153 peers (their median 6.8%) NET MARGIN -697.1% · above 1% FCF margin: -458.0%, above 3% of 144 peers (their median 10.1%) FCF MARGIN -458.0% · above 3%
RXRX Peer median Below the median

What changed

14 new risk paragraphs and 2 accounting facts worth reading about. 10-K filed Feb 25, 2026 against Feb 28, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

9 checks on the latest 10-K. Checks, not verdicts.

How it works

2facts worth reading about the other 7 checks found nothing to note

  • Critical audit matters changed
    New this year: External Research and Development Expenses (“As described in Note 2 to the consolidated financial statements, research and development expenses comprise of costs incurred in performing research and development activities (other than those performed pursuant to contracts with customers, which are recorded as revenue), including drug discovery a”). No longer listed: Acquisition of Exscientia plc - Valuation of Platform Technology and In-Process Research and Development
  • Material weakness in internal control
    “Further, in connection with the business combination with Exscientia, material weaknesses related to internal controls over financial reporting were identified related to ineffective process and controls, which resulted in an immaterial misstatement to unearned revenue and unearned revenue, non-current in our consolidated financial statements as of and for the year ended December 31, 2024, which remain unremediated as of December 31, 2025 (see “Part II - Item 9A - Controls and Procedures” for fu”
  • Cash from operations −$371.8M vs net income −$644.8M (FY ending Dec 31, 2025)
6 more checks with nothing to note
  • Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

14 paragraphs in Risk Factors that were not in the 10-K filed Feb 28, 2025. Quoted as filed.

All 14 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    Increasing scrutiny and changing expectations from governments, regulators, and third-parties relating to environmental, social and governance (ESG) policies and practices may cause us to incur additional costs, expose us to additional risks or impact our reputation. In recent years, there has been increasing public focus and scrutiny…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    We currently have operations in the United States (Salt Lake City and New York), The United Kingdom (London and Milton Park) and Canada (Montreal). While these locations are in or near major biotechnology and technology hubs,
  3. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    If we achieve success in our clinical trials, we would need to scale our operations to support commercialization, and we may encounter difficulties in managing this growth. While we do not anticipate significant growth in our workforce or the scope of our operations in the near-term, our long-term strategy depends on the successful…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    We may acquire additional businesses, products, form strategic alliances, or create joint ventures and we may not realize the benefits of such transactions.

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$39.8M$44.6M$58.8M$74.7M
Net income−$239.5M−$328.1M−$463.7M−$644.8M
Operating cash flow−$83.5M−$287.8M−$359.2M−$371.8M
Free cash flow−$120.6M−$299.7M−$372.9M−$378.3M

Revenue, FY2019 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$74.7M ▲ 26.9% in FY2025

FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

3 filings in the last 30 days · SEC EDGAR

All filings

About the company

Recursion Pharmaceuticals, Inc., Salt Lake City, UT · from the 10-K filed Feb 25, 2026

Recursion is a clinical-stage TechBio company with a mission to decode biology to radically improve lives. We have advanced a portfolio of differentiated internal programs and strategic partnerships powered by our integrated drug discovery and development platform, the Recursion Operating System (OS). This platform provides end-to-end, AI-native capabilities that span from novel biological ideas through the clinic, integrating multimodal biological data generation, AI-powered small molecule synthesis, and AI-enabled clinical development. All of our technologies are designed to translate complex science into medicines that matter - faster, better, and at scale - for patients who are waiting.

Headquarters
Salt Lake City, UT
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 2, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 25, 2026 (open at SEC), compared with the 10-K filed Feb 28, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RXRX/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.